Modeling RBE-weighted dose variations in irregularly moving abdominal targets treated with carbon ion beams.
Med Phys
2020
47
7
2768-2778
Targeted Natural Killer Cell-Based Adoptive Immunotherapy for the Treatment of Patients with NSCLC after Radiochemotherapy: A Randomized Phase II Clinical Trial.
Clin Cancer Res
2020
26
20
5368-5379
Intraventricular neuroepithelial tumors: surgical outcome, technical considerations and review of literature.
BMC Cancer
2020
20
1
The Role of miRNA for the Treatment of MGMT Unmethylated Glioblastoma Multiforme.
Cancers (Basel)
2020
12
5
First statement on preparation for the COVID-19 pandemic in large German Speaking University-based radiation oncology departments.
Radiat Oncol
2020
15
1
RADIANCE - Radiochemotherapy with or without Durvalumab in the treatment of anal squamous cell carcinoma: A randomized multicenter phase II trial.
Clin Transl Radiat Oncol
2020
23
43-49
Efficacy of PSMA ligand PET-based radiotherapy for recurrent prostate cancer after radical prostatectomy and salvage radiotherapy.
BMC Cancer
2020
20
1
Comparison of GeneChip, nCounter, and Real-Time PCR-Based Gene Expressions Predicting Locoregional Tumor Control after Primary and Postoperative Radiochemotherapy in Head and Neck Squamous Cell Carcinoma.
J Mol Diagn
2020
22
6
801-810
Prognostic risk classification for biochemical relapse-free survival in patients with oligorecurrent prostate cancer after [68Ga]PSMA-PET-guided metastasis-directed therapy.
Eur J Nucl Med Mol Imaging
2020
47
10
2328-2338
Definition and quality requirements for stereotactic radiotherapy: consensus statement from the DEGRO/DGMP Working Group Stereotactic Radiotherapy and Radiosurgery.
Strahlenther Onkol
2020
196
5
417-420